The Trusted Source For Health
A sanitation room in Vail Health’s new medical center in Dillon is pictured Aug. 27. The sanitation rooms are directly beneath the operating rooms, which will perform orthopedic and pain management procedures.Michael Yearout/For the Summit Daily News When Vail Health officially opened its Dillon Health …
There are no “good” foods and “bad” foods. Rather, it’s your overall dietary pattern that matters most when it comes to healthful eating. That’s the main message from the American Heart Association in its latest nutrition guidelines to improve the hearts and health of Americans …
Park, J. Y. & Wu, L. T. Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review. Drug. Alcohol. Depend. 177, 1–13. https://doi.org/10.1016/j.drugalcdep.2017.03.009 (2017).
Epidyolex|European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex (2021).
Anwar, A., Saleem, S., Patel, U. K., Arumaithurai, K. & Malik, P. Dravet syndrome: An overview. Cureus https://doi.org/10.7759/cureus.5006 (2019).
Asadi-Pooya, A. A. Lennox-Gastaut syndrome: A comprehensive review. Neurol. Sci. 393(39), 403–414 (2017).
Swaminath, A. et al. The role of cannabis in the management of inflammatory bowel disease: a review of clinical, scientific, and regulatory informationcommissioned by the crohn’s and colitis foundation. Inflamm. Bowel Dis. 25, 427–435. https://doi.org/10.1093/ibd/izy319 (2019).
Aran, A., Cassuto, H., Lubotzky, A., Wattad, N. & Hazan, E. Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study. J. Autism Dev. Disord. 49, 1284–1288. https://doi.org/10.1007/s10803-018-3808-2 (2019).
Ben-Zeev, B. Medical cannabis for intractable epilepsy in childhood: A review. Rambam Maimonides Med. J. 11, e0004. https://doi.org/10.5041/RMMJ.10387 (2020).
Tramèr, M. R. et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. Br. Med. J. 323, 16–21. https://doi.org/10.1136/bmj.323.7303.16 (2001).
Pacher, P., Kogan, N. M. & Mechoulam, R. Beyond THC and endocannabinoids. Annu. Rev. Pharmacol. Toxicol. 60, 637–659. https://doi.org/10.1146/annurev-pharmtox-010818-021441 (2020).
Skrypek, M. M., Bostrom, B. C. & Bendel, A. E. Medical cannabis certification in a large pediatric oncology center. Children 6, 79. https://doi.org/10.3390/children6060079 (2019).
National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 58,91,97,245 (Washington, DC: The National Academies Press. 2017), DOI: https://doi.org/10.17226/24625.
Bourgeois, F. T. et al. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics 130, 285–292. https://doi.org/10.1542/peds.2012-0139 (2012).
Mueller, B. U. et al. Principles of pediatric patient safety: Reducing harm due to medical care. Pediatrics 143, 2. https://doi.org/10.1542/peds.2012-0139 (2019).
Volkow, N. D., Baler, R. D., Compton, W. M. & Weiss, S. R. B. Adverse health effects of marijuana use. N. Engl. J. Med. 370, 2219–2227. https://doi.org/10.1056/NEJMra1402309 (2014).
Kelly, B. F. & Nappe, T. M. Cannabinoid Toxicity. Treasure Island (FL): StatPearls (StatPearls Publishing, 2019). PMID: 29489164.
Martín-Gómez, A., Palacios-Gómez, M. E. & García-Marcos, S. A. Severe intradialytic hypoglycemia associated with marijuana use. Nefrologia. 35, 328–329. https://doi.org/10.1016/j.nefroe.2015.02.001 (2015).
Naji, L. et al. The association between cannabis use and suicidal behavior in patients with psychiatric disorders: an analysis of sex differences. Biol. Sex Differ. 9, 22. https://doi.org/10.1186/s13293-018-0182-x (2018).
Ragazzi, T. C. C., Shuhama, R., Menezes, P. R. & Del-Ben, C. M. Cannabis use as a risk factor for psychotic-like experiences: A systematic review of non-clinical populations evaluated with the Community Assessment of Psychic Experiences. Early Interv. Psychiatry 12, 1013–1023. https://doi.org/10.1111/eip.12693 (2018).
Lev-Ran, S. et al. The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychol. Med. 44, 797–810. https://doi.org/10.1017/S0033291713001438 (2014).
van Gastel, W. A. et al. Change in cannabis use in the general population: A longitudinal study on the impact on psychotic experiences. Schizophr. Res. 157, 266–270. https://doi.org/10.1016/J.SCHRES.2014.04.023 (2014).
Appelboam, A. & Oades, P. J. Coma due to cannabis toxicity in an infant. Eur. J. Emerg. Med. 13, 177–179. https://doi.org/10.1097/01.mej.0000194405.38206.f2 (2006).
Carstairs, S. D., Fujinaka, M. K., Keeney, G. E. & Ly, B. T. Prolonged coma in a child due to hashish ingestion with quantitation of THC metabolites in urine. J. Emerg. Med. 41, 3. https://doi.org/10.1016/j.jemermed.2010.05.032 (2011).
Bonkowsky, J. L., Sarco, D. & Pomeroy, S. L. Ataxia and shaking in a 2-year-old girl: Acute marijuana intoxication presenting as seizure. Pediatr. Emerg. Care. 21, 527–528. https://doi.org/10.1097/01.pec.0000173349.38024.33 (2005).
Richards, J. R., Smith, N. E. & Moulin, A. K. Unintentional cannabis ingestion in children: A systematic review. J. Pediatr. 190, 142–152. https://doi.org/10.1016/j.jpeds.2017.07.005 (2017).
Corsi, D. J. et al. Maternal cannabis use in pregnancy and child neurodevelopmental outcomes. Nat. Med. 26, 1536–1540. https://doi.org/10.1038/s41591-020-1002-5 (2020).
Sadhana, D., Kathleen, M. & Jonathan, D. K. Marijuana and the pediatric population. Pediatrics https://doi.org/10.1542/peds.2019-2629 (2020).
Wong, S. S. & Wilens, T. E. Medical cannabinoids in children and adolescents: A systematic review. Pediatrics 140, 5. https://doi.org/10.1542/peds.2017-1818 (2017).
Devinsky, O. et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N. Engl. J. Med. 376, 2011–2020. https://doi.org/10.1056/NEJMoa1611618 (2017).
Porcari, G. S., Fu, C., Doll, E. D., Carter, E. G. & Carson, R. P. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Epilepsy Behav. 80, 240–246. https://doi.org/10.1016/j.yebeh.2018.01.026 (2018).
Devinsky, O. et al. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N. Engl. J. Med. 378, 1888–1897. https://doi.org/10.1056/NEJMoa1714631 (2018).
Lattanzi, S. et al. Efficacy and safety of cannabidiol in epilepsy: A systematic review and meta-analysis. Drugs 78, 1791–1804. https://doi.org/10.1007/s40265-018-0992-5 (2018).
de Carvalho, R. R., Almeida, K. J., da Silva, L. L., de Melo Mendes, C. M. & Bor-Seng-Shu, E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy Behav. 102, 106635. https://doi.org/10.1016/j.yebeh.2019.106635 (2020).
Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700. https://doi.org/10.1136/bmj.b2700 (2009).
Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 5(210), 1. https://doi.org/10.1186/s13643-016-0384-4 (2016).
Sterne, J. A. et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355, i4919. https://doi.org/10.1136/bmj.i4919 (2016).
Higgins, J. P. T. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, i7829. https://doi.org/10.1136/bmj.d5928 (2011).
Busner, J. & Targum, S. D. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiat. Edgmont 4(7), 28–37 (2007).
European Medicines Agency. Important medical event terms list (MedDRA version 23.0, updated). https://www.ema.europa.eu/en/documents/other/important-medical-event-terms-list-version-meddra-version-221_en.xls (2020).
Viechtbauer, W. Conducting meta-analyses in R with the metafor. J. Stat. Softw. 36, 1–48. https://doi.org/10.18637/jss.v036.i03 (2010).
Balduzzi, S., Rücker, G. & Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based. Ment. Health 22, 153–160. https://doi.org/10.1136/ebmental-2019-300117 (2019).
Rücker, G., Krahn, U., König, J., Efthimiou, O. & Schwarzer, G. Package ‘netmeta’ title network meta-analysis using frequentist methods. Epidemiol. Health https://doi.org/10.1007/978-3-319-21416 (2020).
McGrath, S., Zhao, X., Steele, R. & Benedetti, A. Package ‘metamedian’ Title Meta-Analysis of Medians. (2020). https://doi.org/10.1002/sim.8013.
Copenhagen Trial Unit. Trial Sequential Analysis Viewer. (2016).
Wetterslev, J., Thorlund, K., Brok, J. & Gluud, C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med. Res. Methodol. 91(9), 1–12. https://doi.org/10.1186/1471-2288-9-86 (2009).
Borenstein, M., Hedges, L., Higgins, J., Rothstein, H. & Biostat Englewood, N.J. Comprehensive Meta-Analysis 3. (2013).
Dean, A.G., Sullivan, K.M., Soe, M.M. OpenEpi: Open source epidemiologic statistics for public health, Version. www.OpenEpi.com, updated 2013/04/06, accessed 2021/10/16.
Page, M. J. et al. Epidemiology and reporting characteristics of systematic reviews of biomedical research: A cross-sectional study. PLOS Med. 13, e1002028. https://doi.org/10.1371/journal.pmed.1002028 (2016).
Chan, S. G., Correia, A. J. & MecLeod, M. S. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial. Pediatrics 79(6), 946–952 (1987).
Dalzell, A. M., Bartlett, H. & Lilleyman, J. S. Nabilone: An alternative antiemetic for cancer chemotherapy. Arch. Dis. Child. 61, 502–505. https://doi.org/10.1136/adc.61.5.502 (1986).
Miller, I. et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: A randomized clinical trial. JAMA Neurol. 77, 613–621. https://doi.org/10.1001/jamaneurol.2020.0073 (2020).
Fairhurst, C., Kumar, R., Checketts, D., Tayo, B. & Turner, S. Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Dev. Med. Child Neurol. 62, 1031–1039. https://doi.org/10.1111/dmcn.14548 (2020).
Efron, D. et al. A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability. Br. J. Clin. Pharmacol. 87, 436–446. https://doi.org/10.1111/bcp.14399 (2021).
Aran, A. et al. Cannabinoid treatment for autism: A proof-of-concept randomized trial. Mol. Autism 12, 1–11. https://doi.org/10.1186/S13229-021-00420-2 (2021).
Devinsky, O. et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology 90, e1204–e1211. https://doi.org/10.1212/WNL.0000000000005254 (2018).
Chesney, E. et al. Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 45, 1799–1806. https://doi.org/10.1038/s41386-020-0667-2 (2020).
Malyshevskaya, O. et al. Natural (∆ 9 -THC) and synthetic (JWH-018) cannabinoids induce seizures by acting through the cannabinoid CB 1 receptor. Sci. Rep. 2017(7), 1–8. https://doi.org/10.1038/s41598-017-10447-2 (2017).
FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms (2018).
Ruggiero, A. et al. Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment. J. Int. Med. Res. 46, 2149–2156. https://doi.org/10.1177/0300060518765324 (2018).
NICE. Cannabis-based medicinal products: [A] Evidence review for intractable nausea and vomiting NICE guideline NG144 Evidence review underpinning recommendations 1.1.1 and 1.1.2 in the NICE guideline. (2019).
Huestis, M. A. et al. Cannabidiol adverse effects and toxicity. Curr. Neuropharmacol. 17, 974–989. https://doi.org/10.2174/1570159×17666190603171901 (2019).
Stockings, E. et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J. Neurol. Neurosurg. Psychiat. 89, 741–753. https://doi.org/10.1136/JNNP-2017-317168 (2018).
Wiley, J. L. et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br. J. Pharmacol. 145, 293. https://doi.org/10.1038/SJ.BJP.0706157 (2005).
Jankowska, B. I., Jankowski, M. M. & Swiergiel, A. H. Cannabidiol decreases body weight gain in rats: involvement of CB2 receptors. Neurosci. Lett. 490, 82–84. https://doi.org/10.1016/J.NEULET.2010.12.031 (2011).
Skluzacek, J. V., Watts, K. P., Parsy, O., Wical, B. & Camfield, P. Dravet syndrome and parent associations: The IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia 52, 95–101. https://doi.org/10.1111/j.1528-1167.2011.03012.x (2011).
Bandini, L. G. et al. Changes in food selectivity in children with autism spectrum disorder. J. Autism Dev. Disord. 47, 439–446. https://doi.org/10.1007/s10803-016-2963-6 (2017).
Di Marzo, V. & Piscitelli, F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics 12, 692. https://doi.org/10.1007/s13311-015-0374-6 (2015).
Zou, S. & Kumar, U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci. 1, 9. https://doi.org/10.3390/ijms19030833 (2018).
Netzahualcoyotzi, C., Rodríguez-Serrano, L. M., Chávez-Hernández, M. E. & Buenrostro-Jáuregui, M. H. Early consumption of cannabinoids: From adult neurogenesis to behavior. Int. J. Mol. Sci. 22, 7450. https://doi.org/10.3390/ijms22147450 (2021).
Solowij, N. et al. Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: A pragmatic open-label clinical trial. Cannabis Cannabinoid. Res. 3, 21–34. https://doi.org/10.1089/can.2017.004 (2018).
Osborne, A. L., Solowij, N. & Weston-Green, K. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Neurosci. Biobehav. Rev. 72, 310–324. https://doi.org/10.1016/j.neubiorev.2016.11.012 (2017).
Sidik, K. & Jonkman, J. N. A comparison of heterogeneity variance estimators in combining results of studies. Stat. Med. 26, 1964–1981 (2007).
There are a lot of decisions to make in December. I’m not just talking about deciding what you buy mum or dad: you have to decide whether you feel comfortable socialising, the financial burden of doing so and – if you are ready to party …
But just what does that mean? If you look at self-care products to buy this holiday season, you’ll find an emphasis on warm baths with soothing bath salts, plushy towels and silky lotions. Don’t forget self-care makeup, nail, massage and detox sets, Business Loan. Calming …
Nearly a quarter of Monroe County’s 5-11 aged children have received their first dose of the COVID-19 vaccine, but many parents are still wrestling with the question: Should I get my child vaccinated?
Last week, Monroe County Board of Health member and retired pediatrician Dr. Carol Litten Touloukian hosted a town hall with local pediatricians Dr. Scot Moore, Dr. Jim Laughlin and Dr. Jason Simmonds to answer that question and many others, Art Of Landscaping.
Dr. Moore currently serves as chairman of the IU Health Bloomington Infection Control Committee. Dr. Laughlin is the chief practice officer of IU Health Southern Indiana Physicians and a volunteer pediatric consultant for Monroe County Community School Corporation district. Dr. Simmonds is the medical director for Riley Physicians in the South Central Region of Indiana.
Here are some of the common questions that were asked during Wednesday’s town hall.
Indiana residents can find and schedule an appointment nearby at ourshot.in.gov. Due to high demand, vaccine appointments in Monroe County are mostly booked through the year, but residents are encouraged to frequently check back, in case there have been cancellations.
If appointments are not available locally, health officials urge residents to look in nearby counties, such as Brown, Lawrence or Greene, that do not have the same level of demand as Monroe.
The child vaccine is also available at various pediatric offices and local pharmacies.
Yes, it is different. The approved Pfizer vaccine for people aged 5-11 is only a third of the amount of an adult dosage.
Because of that, pediatricians are seeing fewer short-term side effects in that age group, Simmonds said.
More:County outpaces state in 5-11 child vaccination rate as youth COVID cases surge nationwide
People can experience pain, redness, or swelling where the injection was given. They can also have mild symptoms such as headache, muscle pain, fever, chills or fatigue. These side effects usually go away after one to two days.
“Not that there can’t be some side effects, but I think overall we’ve definitely seen less. I’ve not had, from personal reports, any of my patients report significant side effects from the vaccine,” Simmonds said.
Yes, children who have already had COVID-19 should still be vaccinated.
“For COVID itself, the immunity varies for that. So you may not get as long-lasting immunity (from the virus) as you might get from the vaccine, so there’s no need to wait,” Simmonds said.
According to the U.S. Centers of Disease Control and Prevention, research has not yet shown how long one is protected from getting COVID-19 again after they recover.
Residents should wait until they have recovered from COVID-19 before they get the vaccine.
“It is definitely fine to go ahead and get (the COVID-19 vaccine) at the same time as the flu vaccine. There’s no need to spread that apart,” Simmonds said.
Right now, Monroe County, like most areas of the country, is experiencing the height of flu season.
More:COVID cases on the rise again in Monroe County; fewer people taking protective measures
“We are seeing flu in our community right now, so it’s important to get your child the flu vaccine as soon as possible,” Simmonds said.
Several pediatric offices and clinics offer both the flu and COVID-19 vaccine in tandem.
Yes, someone with an egg allergy can receive the vaccine. The COVID-19 vaccines that currently are authorized by the FDA, including the Pfizer vaccine, are not manufactured using egg products or egg culture.
Children tend to have mild cases of COVID-19, but many have been hospitalized or died as a result of COVID-19.
Currently, 25{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d} of all COVID-19 cases nationwide are in children under the age of 18. In the United States, there were more than 20,400 hospitalizations of children as of early September and 731 child deaths due to the virus as of Nov. 24.
For the past several months, COVID-19 has been in the top 10 leading causes of death in children in the United States.
While these cases are mostly mild, children with COVID-19 can also contribute to spreading the virus around the community to infect others who are more vulnerable.
“We’ve already identified that (COVID-19) has a significant mortality in certain age groups and in people who have comorbid conditions and immune-compromised conditions, so vaccinating the healthy kids that are likely to still spread it to these people is our priority,” Laughlin said.
Even children who have mild cases of COVID-19 or are asymptomatic can run the risk of suffering long-term effects.
According to Moore, between 10{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d} and 20{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d} of children who have had COVID-19 also have developed “long COVID,” which can occur within three months after infection and lasts for at least two months. Some symptoms of this condition include fatigue, shortness of breath and cognitive dysfunction (commonly referred to as “brain fog”).
While younger people are more likely to be asymptomatic or have mild symptoms, the COVID-19 virus can have long-term effects such as multisystem inflammatory syndrome in children or long COVID.
While extremely rare, MIS-C is a serious and life-threatening condition that can occur two to six weeks after the COVID-19 infection. It prompts an autoimmune response that causes inflammation in several parts of the body, including lungs, heart, skin, kidneys, brain or stomach. According to the town hall panelists, 75{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d} to 90{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d} of cases have occurred in children who were considered healthy prior to COVID-19. The Centers for Disease Control and Prevention is still studying MIS-C and how it affects children; the CDC is still unsure why some children have gotten sick with MIS-C while most others have not.
Only 142 cases of MIS-C have been identified in Indiana so far.
In contrast to the virus’ long-term impact, the COVID-19 vaccine has not demonstrated any lasting negative impacts.
According to several panelists, within all the vaccines that have ever been developed, any significant long-term complications have been recognized within the first six months of it being used on the population. It is unlikely that the public will have any new long-term consequences.
In all U.S. age groups, a very low number of deaths (0.0022{b574a629d83ad7698d9c0ca2d3a10ad895e8e51aa97c347fc42e9508f0e4325d}) have occurred following a COVID-19 vaccination, according to the CDC, and in many of those cases something other than the vaccine may have been the cause of death.
Myocarditis occurs when the body’s immune system causes inflammation of the heart muscle in response to an infection or some other trigger, as defined by the CDC.
According to the CDC, since April 2021, there has been an increase in U.S. cases of myocarditis following COVID-19 vaccination, predominantly in male teenagers and young adults. The symptoms typically present within a few days after the vaccine, especially the second dose. The CDC and its partners are currently investigating these cases.
Most of these cases, as rare as they are, are mild and do not lead to hospitalization. Patients who seek medical care and rest have recovered very quickly.
“It’s not a reason (to) not get the vaccine,” Simmonds said.
The panelists confirmed they had not seen any report of children aged 5-11 with myocarditis after being vaccinated.
There have been some case reports of myocarditis following COVID-19 infection.
“I’ve been in multiple meetings with infectious disease experts where they’ll tell you that the virus itself is much more likely to cause myocarditis than the vaccine,” Simmonds said.
“I would not recommend waiting. I would get it as soon as you’re able to just because you’re delaying that time. You could catch it during that time that you’re waiting,” Simmonds answered.
It has also been fine to mix doses for children on that age cusp, according to Simmonds. While they are still 11, the child can receive the 5-11 vaccine dose. If they have since turned 12 when it’s time for that second shot, they can receive the adult dosage.
“I don’t typically recommend it. I don’t think there’s really a problem with it,” Simmonds said. “My advice to my patients is if they have side effects after the vaccine, it’s fine to give Tylenol or ibuprofen if they’re achy or feverish, which does happen. At that point, give Tylenol or ibuprofen.”
Laughlin said he could not say for certain whether a vaccine for COVID-19 could be required at schools.
“We don’t require flu vaccines, but we encourage them,” Laughlin added.
Laughlin, and many other health officials, hope that COVID-19 will become like other mild viruses that cause some symptoms but do not lead to serious illness.
“We also hope that more and more people will get vaccinated so that it becomes a milder virus and doesn’t continue to mutate,” Laughlin said.
“I see it as the way to eventually not have to wear masks at school and to get back to normal life,” Laughlin answered.
Being fully vaccinated gives children reassurance that they are less likely to contract the virus, less likely to have symptoms if contracted and less likely to spread it to others.
“We’re hoping that if we get enough people vaccinated, we’ll have what you would refer to as ‘herd immunity’ so that it’s very unlikely to acquire the virus when you’re around other people,” Laughlin said.
Health officials still don’t know much about the newest variant, Omicron.
According to Laughlin, it appears that the Omicron variant is likely more contagious than the Delta variant, but the severity is still unknown. Over time, as it continues to spread, health officials will have more information.
“Should you wait to get the vaccine now until we know more about the Omicron variant? I would say definitely not because that’s going to take a while for any change in vaccine to come out if they do decide to change the vaccine,” Laughlin said. “We don’t even know that we’re going to need to change the vaccine to provide protection.”
So far, the FDA-approved vaccines have been highly effective in all other previous variants.
“Based on current knowledge, there’s no reason to wait,” Laughlin concluded.
Pfizer is currently conducting clinical trials of its vaccine in children ages 6 months to 4 years. Laughlin estimated that the vaccine for that age group could be approved in late winter or early spring of 2022.
In the meantime, families are encouraged to get their children aged 5 and older vaccinated to protect their younger siblings.
Residents are also encouraged to be masked where unvaccinated people might be, such as community gatherings. Monroe County currently has a health order that requires masking, regardless of vaccination status, in indoor public spaces.
“I think that boosters likely will be necessary. We don’t know that yet,” More said. “We started giving vaccine to 12- to 15-year-olds in May, so we will have six months of information on that pretty soon.”
A COVID booster shot is an additional dose of the vaccine some time following the original dosages, which have demonstrated decreased protection over time.
“With a lot of the world yet to be vaccinated, including many people in the United States, it’s likely that there will be more variants over time, and if they are more transmissible and whatever the severity is, we may need boosters. To this point, the vaccine that we have right now is really very protective for most all of us,” Moore said.
The current recommendation by the CDC is anyone over 18 should receive a booster shot six months after their second shot.
Residents interested in watching the full town hall can find a recording on https://catstv.net/.
Contact Rachel Smith at rksmith@heraldt.com or @RachelSmithNews on Twitter.
Visit : https://ilandscapin.com/